Benitec Biopharma Inc. (BNTC) stock
Close on Nov 11, 2026Market cap $330.34MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $330.34M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.87
- Dividend yield
- –
- Free cash flow yield
- -5.03%
Fundamentals
- Net income
- -$45.55M
- EPS, diluted
- -$0.98
- Free cash flow
- -$16.62M
- Book value per share
- $3.58
- Diluted shares
- 49M
Trading
- Next earnings
- Nov 13, 2026 (estimated, after the close)
- Previous close
- $9.28
- Open
- $9.42
- Day's range
- $9.20 – $9.59
- Volume
- 120,638
- Average volume (20 days)
- 193,046
- Index membership
- Russell 2000 (since Jun 2025)
- Beta (5 years)
- 1.13
- 52-week range
- $7.88 – $14.39
- RSI (14 days)
- 53.0
- Volatility (1 year)
- 57.7%
- Relative volume
- 0.75×
- WACC
- 10.5%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | BNTC | S&P 500 | Difference | BNTC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +6.8% | -2.4% | +9.2 pts | ||
| 3 months | -29.7% | -1.2% | −28.6 pts | ||
| Year to date | -29.7% | +12.3% | −42.0 pts | ||
| 1 year | -28.6% | +12.4% | −41.0 pts | ||
| 3 years | +176.9% | +78.8% | +98.1 pts | +40.4% | +21.4% |
| 5 years | -83.9% | +75.2% | −159.0 pts | -30.6% | +11.9% |
| 10 years | -97.6% | +311.1% | −408.7 pts | -31.2% | +15.2% |
Nine years at a glance
Fiscal years 2018 to 2026, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Benitec Biopharma filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Results
- Results
- Results
About Benitec Biopharma
Pharmaceutical Preparations
Benitec Biopharma Inc. is a clinical-stage biotechnology company that develops genetic medicines. The company utilizes a therapeutic platform combining gene silencing with functional gene replacement delivered through viral vectors. Its primary product candidate is BB-301, an investigational gene therapy designed to treat oculopharyngeal muscular dystrophy, a chronic degenerative muscle disorder. The company aims to serve patients suffering from this condition. Additionally, it engages with larger biopharmaceutical firms as commercial partners through potential co-development collaborations and out-licensing agreements.
Company profile, executives and historyBenitec Biopharma stock: common questions
What is Benitec Biopharma's stock price?
BNTC closed at $9.47 on Nov 11, 2026, up 2.05% on the day. Over the past 52 weeks it traded between $7.88 and $14.39.
What is Benitec Biopharma's market cap?
Benitec Biopharma was worth $330.34M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is BNTC's P/E ratio?
Benitec Biopharma lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.98), so it has no meaningful P/E ratio.
Does Benitec Biopharma pay a dividend?
No. Benitec Biopharma has not paid a cash dividend over the last twelve months.
When does Benitec Biopharma report earnings next?
Benitec Biopharma is expected to report Q1 FY2027 results on Nov 13, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has BNTC stock performed over the past year?
Including dividends, BNTC returned -28.6% over the past year, against +12.4% for the S&P 500.
How many BNTC shares are sold short?
2M shares were sold short at the latest FINRA report, 27.86% of the float, or 11.3 days of average trading volume.
Who are Benitec Biopharma's competitors?
Companies most similar to Benitec Biopharma by business, industry and size include PEPG, QURE, SRPT, TRDA, DYN.
See a number that looks wrong?